$136.64 Million in Sales Expected for Natus Medical Inc (BABY) This Quarter

Equities research analysts forecast that Natus Medical Inc (NASDAQ:BABY) will post sales of $136.64 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Natus Medical’s earnings. The lowest sales estimate is $136.00 million and the highest is $137.32 million. Natus Medical posted sales of $131.44 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 4%. The company is expected to issue its next quarterly earnings results on Wednesday, February 6th.

On average, analysts expect that Natus Medical will report full-year sales of $526.54 million for the current year, with estimates ranging from $525.90 million to $527.22 million. For the next fiscal year, analysts anticipate that the business will report sales of $541.60 million, with estimates ranging from $535.00 million to $553.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Natus Medical.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Wednesday, October 24th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.02). Natus Medical had a positive return on equity of 11.34% and a negative net margin of 3.53%. The company had revenue of $130.60 million for the quarter, compared to analysts’ expectations of $132.92 million. During the same period in the prior year, the company posted $0.40 EPS. The firm’s revenue was up 6.5% compared to the same quarter last year.

BABY has been the topic of a number of recent research reports. BidaskClub raised Natus Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 21st. ValuEngine raised Natus Medical from a “sell” rating to a “hold” rating in a research report on Friday, November 16th. Zacks Investment Research raised Natus Medical from a “sell” rating to a “hold” rating in a research report on Friday, August 10th. Finally, Roth Capital set a $36.00 price objective on Natus Medical and gave the stock a “buy” rating in a research report on Thursday, October 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Natus Medical currently has a consensus rating of “Hold” and an average price target of $42.50.

In related news, insider Jonathan Kennedy sold 47,600 shares of the stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $36.85, for a total value of $1,754,060.00. Following the transaction, the insider now owns 161,628 shares of the company’s stock, valued at $5,955,991.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert A. Gunst sold 14,750 shares of the stock in a transaction on Monday, November 19th. The shares were sold at an average price of $33.54, for a total value of $494,715.00. Following the completion of the transaction, the director now directly owns 32,392 shares in the company, valued at approximately $1,086,427.68. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Natus Medical by 4.6% in the third quarter. BlackRock Inc. now owns 5,013,693 shares of the medical equipment provider’s stock valued at $178,739,000 after buying an additional 220,521 shares during the last quarter. Janus Henderson Group PLC lifted its position in Natus Medical by 14.6% in the third quarter. Janus Henderson Group PLC now owns 3,111,761 shares of the medical equipment provider’s stock valued at $110,934,000 after purchasing an additional 396,772 shares during the period. Vanguard Group Inc. lifted its position in shares of Natus Medical by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,612,432 shares of the medical equipment provider’s stock valued at $93,133,000 after acquiring an additional 58,239 shares during the period. Eagle Asset Management Inc. lifted its position in shares of Natus Medical by 6.8% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,924,407 shares of the medical equipment provider’s stock valued at $68,605,000 after acquiring an additional 123,132 shares during the period. Finally, Carillon Tower Advisers Inc. purchased a new position in shares of Natus Medical during the 2nd quarter worth approximately $41,626,000. 97.72% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Natus Medical stock traded up $0.65 during trading hours on Monday, reaching $33.94. 255,602 shares of the company were exchanged, compared to its average volume of 350,428. Natus Medical has a 1 year low of $27.69 and a 1 year high of $41.55. The company has a current ratio of 2.62, a quick ratio of 1.89 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $1.12 billion, a P/E ratio of 23.41 and a beta of 0.54.

Natus Medical Company Profile

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Story: What is Depreciation?

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply